Report
Biogroup : Biogroup is testing its cost base
Results are sharply down (revenues -29% and EBITDA -48% in H1 2023) owing to the rapid fall in covid testing revenues, related delays to adjust staff costs and inflationary pressure. Conversely, routine revenues performed better than expected (c. +2% organically) as solid volume growth enabled to more than offset a 4.7% regulatory cut in tariffs in France. The outlook should be more favorable in 2024 owing to more moderate tariff cuts in France and the impact of the group’s effic...
Provider
Oddo BHF
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Pierre François Merveille
Other Reports from Oddo BHF
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.